Published in J Med Chem on August 04, 2015
A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen (1999) 32.67
A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature (1997) 10.14
General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc Natl Acad Sci U S A (1985) 8.77
Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature (1997) 6.06
The ADAM metalloproteinases. Mol Aspects Med (2008) 4.34
The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood (2003) 3.51
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell (2006) 3.20
Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem (2001) 2.91
Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet (2003) 2.69
Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet (2009) 2.58
Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol Biol Cell (2006) 2.43
Structural basis for the highly selective inhibition of MMP-13. Chem Biol (2005) 2.33
ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol (2011) 2.19
The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol (2004) 2.19
Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. Comb Chem High Throughput Screen (2005) 1.99
Recent advances in MMP inhibitor design. Cancer Metastasis Rev (2006) 1.66
Strategies for the use of mixture-based synthetic combinatorial libraries: scaffold ranking, direct testing in vivo, and enhanced deconvolution by computational methods. J Comb Chem (2007) 1.66
Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins beta1 and beta2. Dev Biol (2005) 1.63
Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase. Biochem Biophys Res Commun (2003) 1.58
Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol (2008) 1.54
Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie (2007) 1.49
Advances in the use of synthetic combinatorial chemistry: mixture-based libraries. Nat Med (2003) 1.43
A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum (2009) 1.38
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem (2007) 1.37
Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum (2003) 1.26
Cross-domain inhibition of TACE ectodomain. Proc Natl Acad Sci U S A (2011) 1.26
MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease. Oncogene (2007) 1.19
The Wnt/planar cell polarity protein-tyrosine kinase-7 (PTK7) is a highly efficient proteolytic target of membrane type-1 matrix metalloproteinase: implications in cancer and embryogenesis. J Biol Chem (2010) 1.17
Novel selective MMP-13 inhibitors reduce collagen degradation in bovine articular and human osteoarthritis cartilage explants. Inflamm Res (2009) 1.12
γ-Secretase inhibitors and modulators for Alzheimer's disease. J Neurochem (2011) 1.09
Current perspective of TACE inhibitors: a review. Bioorg Med Chem (2008) 1.09
Regulation of interleukin-8 via an airway epithelial signaling cascade. Am J Physiol Lung Cell Mol Physiol (2007) 1.04
Selective agonists and antagonists of formylpeptide receptors: duplex flow cytometry and mixture-based positional scanning libraries. Mol Pharmacol (2013) 1.03
Membrane type-1 matrix metalloproteinase confers aneuploidy and tumorigenicity on mammary epithelial cells. Cancer Res (2006) 1.03
High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem (2008) 1.03
Discovery of novel inhibitors of a disintegrin and metalloprotease 17 (ADAM17) using glycosylated and non-glycosylated substrates. J Biol Chem (2012) 1.02
ADAM17, shedding, TACE as therapeutic targets. Pharmacol Res (2013) 1.01
Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis. Ann Rheum Dis (2009) 1.00
Shedding of discoidin domain receptor 1 by membrane-type matrix metalloproteinases. J Biol Chem (2013) 1.00
Targeting ADAMS and ERBBs in lung cancer. Cancer Cell (2006) 0.96
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. Bioorg Med Chem (2008) 0.96
Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation. Trends Pharmacol Sci (2014) 0.95
EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments. J Dermatol Sci (2009) 0.95
Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. J Med Chem (2008) 0.94
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. Bioorg Med Chem Lett (2011) 0.94
Potential relation of aberrant proteolysis of human protein tyrosine kinase 7 (PTK7) chuzhoi by membrane type 1 matrix metalloproteinase (MT1-MMP) to congenital defects. J Biol Chem (2011) 0.92
Synthetic active site-directed inhibitors of metzincins: achievement and perspectives. Mol Aspects Med (2008) 0.92
Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site. Chem Biol (2012) 0.89
Insights into ectodomain shedding and processing of protein-tyrosine pseudokinase 7 (PTK7). J Biol Chem (2012) 0.88
Novel TACE inhibitors in drug discovery: a review of patented compounds. Expert Opin Ther Pat (2010) 0.88
Two High Throughput Screen Assays for Measurement of TNF-α in THP-1 Cells. Curr Chem Genomics (2011) 0.85
Activity of ADAM17 (a disintegrin and metalloprotease 17) is regulated by its noncatalytic domains and secondary structure of its substrates. J Biol Chem (2013) 0.84
Downstream signaling and genome-wide regulatory effects of PTK7 pseudokinase and its proteolytic fragments in cancer cells. Cell Commun Signal (2014) 0.83
Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site. Bioorg Med Chem (2014) 0.83
Novel methods and strategies in the discovery of TACE inhibitors. Expert Opin Drug Discov (2012) 0.82
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. J Med Chem (2014) 0.82
Protein-tyrosine pseudokinase 7 (PTK7) directs cancer cell motility and metastasis. J Biol Chem (2014) 0.81
Smooth muscle cells relay acute pulmonary inflammation via distinct ADAM17/ErbB axes. J Immunol (2013) 0.81
Production of soluble Neprilysin by endothelial cells. Biochem Biophys Res Commun (2014) 0.81
How chemistry supports cell biology: the chemical toolbox at your service. Trends Cell Biol (2014) 0.81
Allosteric inhibition of BACE1 by an exosite-binding antibody. Curr Opin Struct Biol (2013) 0.80
ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival. Tumour Biol (2013) 0.80
Advances in studies on collagenase inhibitors. EXS (2012) 0.76